Pro-inflammatory cytokine (IL-6) and total count lymphocyte profiles in COVID-19 patients with different severity levels

S. Sari, Wening Tri Mawanti, Dewi Martalena, E. Listiyaningsih, Rizkyana Avissa, Rini Latifah, W. Sukarya
{"title":"Pro-inflammatory cytokine (IL-6) and total count lymphocyte profiles in COVID-19 patients with different severity levels","authors":"S. Sari, Wening Tri Mawanti, Dewi Martalena, E. Listiyaningsih, Rizkyana Avissa, Rini Latifah, W. Sukarya","doi":"10.19106/jmedsci005303202101","DOIUrl":null,"url":null,"abstract":"COVID-19 is caused by the SARS-CoV-2 infection that attacked the human respiratory system. In severe conditions it causes pneumonia, kidney failure, acute respiratory distress syndrome (ARDS) and even death. The SARS-CoV-2 infection triggers the immune cells to secrete an excess of pro-inflammatory cytokines that lead to cytokine storm. It is believed to become one of the mechanisms that cause the ARDS condition. The level of pro-inflammatory cytokines will differ with each case severity. This study aimed to evaluate the profile of pro-inflammatory cytokines in COVID-19 patients with different severity. Therefore, it could be used as a therapeutic approach for cytokine storm conditions. It was a cross sectional study using plasma samples of COVID-19 patients from Jakarta Islamic Hospital Pondok Kopi and Dr. M. Goenawan Partowidigdo Hospital Cisarua Indonesia. The COVID-19 patients with severe (n=20) and mild to moderate (n=25) severity were involved in this study. As a negative control plasma sample from healthy subjects (n=13) was used. Plasma IL-6 levels were measured using the ELISA technique and plasma lymphocyte levels were measured using a hematology analyzer. The results showed that no significant difference between severity and gender was observed (p=0.256). Meanwhile there is a significant difference in IL-6 level between negative control mild-moderate and severe categories (p=0.015). The average IL-6 level in severe categories was higher than mild-moderate and negative control categories with values 105.375 59.75 and 64.577 pg/mL respectively. This result becomes supporting evidence that there is a cytokine storm condition in severe COVID-19 patients. Furthermore, the lymphocyte level in the severe group is significantly lower than the mild to moderate group. This result may indicate lymphocytopenia in the severe group.","PeriodicalId":17474,"journal":{"name":"Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19106/jmedsci005303202101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

COVID-19 is caused by the SARS-CoV-2 infection that attacked the human respiratory system. In severe conditions it causes pneumonia, kidney failure, acute respiratory distress syndrome (ARDS) and even death. The SARS-CoV-2 infection triggers the immune cells to secrete an excess of pro-inflammatory cytokines that lead to cytokine storm. It is believed to become one of the mechanisms that cause the ARDS condition. The level of pro-inflammatory cytokines will differ with each case severity. This study aimed to evaluate the profile of pro-inflammatory cytokines in COVID-19 patients with different severity. Therefore, it could be used as a therapeutic approach for cytokine storm conditions. It was a cross sectional study using plasma samples of COVID-19 patients from Jakarta Islamic Hospital Pondok Kopi and Dr. M. Goenawan Partowidigdo Hospital Cisarua Indonesia. The COVID-19 patients with severe (n=20) and mild to moderate (n=25) severity were involved in this study. As a negative control plasma sample from healthy subjects (n=13) was used. Plasma IL-6 levels were measured using the ELISA technique and plasma lymphocyte levels were measured using a hematology analyzer. The results showed that no significant difference between severity and gender was observed (p=0.256). Meanwhile there is a significant difference in IL-6 level between negative control mild-moderate and severe categories (p=0.015). The average IL-6 level in severe categories was higher than mild-moderate and negative control categories with values 105.375 59.75 and 64.577 pg/mL respectively. This result becomes supporting evidence that there is a cytokine storm condition in severe COVID-19 patients. Furthermore, the lymphocyte level in the severe group is significantly lower than the mild to moderate group. This result may indicate lymphocytopenia in the severe group.
不同严重程度COVID-19患者的促炎细胞因子(IL-6)和淋巴细胞总数
COVID-19是由攻击人类呼吸系统的SARS-CoV-2感染引起的。在严重的情况下,它会导致肺炎、肾衰竭、急性呼吸窘迫综合征(ARDS)甚至死亡。SARS-CoV-2感染触发免疫细胞分泌过量的促炎细胞因子,导致细胞因子风暴。这被认为是导致ARDS的机制之一。促炎细胞因子的水平会随着病情的严重程度而有所不同。本研究旨在评估不同严重程度COVID-19患者的促炎细胞因子特征。因此,它可以作为一种治疗细胞因子风暴的方法。这是一项横断面研究,使用了来自印度尼西亚雅加达伊斯兰医院Pondok Kopi和Dr. M. Goenawan Partowidigdo医院的COVID-19患者的血浆样本。本研究纳入重症(n=20)和轻中度(n=25)的COVID-19患者。阴性对照采用健康受试者(n=13)的血浆样本。采用ELISA技术测定血浆IL-6水平,采用血液学分析仪测定血浆淋巴细胞水平。结果显示,严重程度与性别无显著差异(p=0.256)。阴性对照轻、中度、重度组患者IL-6水平差异有统计学意义(p=0.015)。重度组平均IL-6水平高于轻、中度组和阴性对照组,分别为105.375、59.75和64.577 pg/mL。这一结果成为支持COVID-19重症患者存在细胞因子风暴条件的证据。重度组淋巴细胞水平明显低于轻、中度组。此结果可能提示重症组淋巴细胞减少。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信